At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 175 enrolled
Drug / intervention
NRL-1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)
In Brief
A Phase 3 clinical trial evaluating NRL-1 for Acute Repetitive Seizures and Breakthrough Seizures. Completed, enrolled 175 participants across 5 sites.
Detailed Summary
This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Repetitive Seizures, Breakthrough Seizures
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionJun 2020
Study CompletionJul 2020
TodayJul 2026
First PostedMar 28, 2016
Enrollment StartApr 11, 2016
Primary CompletionJun 17, 2020
Study CompletionJul 23, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.3 years ago
Interventions
NRL-1drug